TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00511277
Drug: Seroquel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
Study: NCT01772823
Drug: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
Study: NCT00805285
Drug: Combination Oral Budesonide and Rectal Hydrocortisone
Normalized name: budesonide Rectal Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
Study: NCT01117129
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion on day 1 and 15
Study: NCT01117129
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25 mg weekly
Study: NCT01840449
Drug: Somatuline Autogel® 60, 90 or 120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01289041
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02209610
Drug: Intrathecal Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mu-opioid receptor agonist
Study: NCT00551135
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00478322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of 100 mg BID
Study: NCT00478322
Drug: INCB013739
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB013739 100 mg BID
Study: NCT00676897
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg PO or NGT
Study: NCT00676897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn Starch
Study: NCT03303677
Drug: Topical Antibacterial (Product)
Normalized name: Dermoplast Antibacterial Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
Study: NCT03743896
Drug: Transdermal Glucosamine Cream
Normalized name: glucosamine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02254083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00803166
Drug: Halobetasol Propionate 0.05% Cream-Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small amount applied and evaluated over the course of three days
Study: NCT00803166
Drug: Halobetasol Propionate 0.05% Cream-Test product 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small amount applied and evaluated over the course of three days
Study: NCT00803166
Drug: Halobetasol Propionate 0.05% Cream-Test Product 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small amount applied and evaluated over the course of three days
Study: NCT01129531
Drug: AGN-214868
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
Study: NCT04570254
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast.
Study: NCT00553605
Drug: Ketoprofen 100mg
Normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
Study: NCT02604485
Drug: Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: XOMA 358 single dose level A administered by an intravenous infusion
Study: NCT02604485
Drug: Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: XOMA 358 single dose level B administered by an intravenous infusion
Study: NCT02604485
Drug: Cohort 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: XOMA 358 single dose level C administered by an intravenous infusion
Study: NCT02604485
Drug: Cohort 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: XOMA 358 single dose level D administered by an intravenous infusion
Study: NCT02931890
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral capecitabine in arm 1 and 2
Study: NCT04169919
Drug: Normal Saline Flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline eye wash
Study: NCT00694733
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection IM monthly for 4 months
Study: NCT00694733
Drug: Depo Lupron/Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
Study: NCT00694733
Drug: Depo Lupron/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
Study: NCT00694733
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Cream 1ml applied twice daily for four months
Study: NCT00647634
Drug: Xanax XR® Tablets (3 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg, single dose fasting
Study: NCT00059228
Drug: 17beta Estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alora 100 microgram per day by skin patch for 6 weeks.
Study: NCT00059228
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo skin patch for 6 weeks
Study: NCT00619983
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4: Will receive placebo pills
Study: NCT00374088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
Study: NCT02794714
Drug: Deep neuromuscular blockade
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
Study: NCT02794714
Drug: Moderate neuromuscular blockade
Normalized name: Blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
Study: NCT00657514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet po bid up to 2 tablets po bid if tolerated
Study: NCT01175564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, single dose and 6 days repeated dose
Study: NCT03493568
Drug: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Normalized name: Genvoya 150mg-150mg-200mg-10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.
Study: NCT03544229
Drug: TAK-906 Maleate
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-906 maleate capsules.
Study: NCT03544229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-906 maleate placebo-matching capsules.
Study: NCT02427841
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03187353
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsule will be filled with microcellulose.
Study: NCT02414347
Drug: F 18 T807
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT03919409
Drug: TS-161
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-161 capsules
Study: NCT03919409
Drug: TS-161 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-161 matching placebo capsules
Study: NCT00376012
Drug: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
Study: NCT00376012
Drug: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
Study: NCT01547520
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
Study: NCT04167228
Drug: Best Available Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with the best available treatment other than ceftazidime-avibactam.
Study: NCT00819403
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
Study: NCT00819403
Drug: ezetimibe/simvastatin
Normalized name: EZETIMIBE/SIMVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
Study: NCT00421226
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04052932
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets，QD
Study: NCT01603342
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
Study: NCT00511797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02680197
Drug: CHF5259 or Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
Study: NCT01492621
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
Study: NCT02238106
Drug: Serevent® Diskus®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02238106
Drug: Placebo HandiHaler®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02238106
Drug: Placebo Diskus®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01891890
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
Study: NCT00365560
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02670252
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT01540812
Drug: Hydrocortisone in induction
Normalized name: hydrocortisone Injection
DrugBank: Hydrocortisone acetate (DB14539)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01540812
Drug: PEG-ASP in consolidation-2
Normalized name: PEG-2 STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02819856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg SPI-1005 bid po x 21d
Study: NCT01540812
Drug: PEG-ASP in consolidation-3
Normalized name: PEG-3 cocamine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02896101
Drug: Elidel® (pimecrolimus) Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01125566
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
Study: NCT02725008
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
Study: NCT02175745
Drug: 18F-fluoro-dihydroxyphenylalanine
Normalized name: 6-Fluoro-(18F)-L-3,4-Dihydroxyphenylalanine
DrugBank: Fluorodopa (18F) (DB13848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously (IV)
Study: NCT00808899
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide
Study: NCT00808899
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin
Study: NCT03774875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets taken orally twice a day
Study: NCT02624375
Drug: Zoster Vaccine Live
Normalized name: zoster vaccine live
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02257918
Drug: AZD0914
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
Study: NCT00135785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02053740
Drug: Routine western medicine
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04440059
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-022 at a dose of 150mg PO QD
Study: NCT00554086
Drug: Escalating dose of Casodex from 50mg daily to 150 mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
Study: NCT00658840
Drug: Capecitabine (Xeloda®)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
Study: NCT01287845
Drug: BAY1075553
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
Study: NCT01287845
Drug: BAY1075553
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
Study: NCT00474383
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
Study: NCT00110955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q3W dosing of placebo
Study: NCT01381627
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
Study: NCT00174798
Drug: SSR240600C
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00174798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01765452
Drug: Closone
Normalized name: erythromycin estolate Oral Capsule [Ilosone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg/100mg, 8weeks, PO
Study: NCT01765452
Drug: Plavix with Astrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg, 100mg a day, 8weeks, PO
Study: NCT03075241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive or inert pill which will be used as a comparator
Study: NCT01865500
Drug: Metil prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01138930
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo daily
Study: NCT03606122
Drug: PD P 506 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²
Study: NCT00499850
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous infusion
Study: NCT02220296
Drug: Insulin 338
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
Study: NCT00002721
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01231464
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02602353
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Placebo Patch applied daily for 3 days
Study: NCT01068405
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
Study: NCT01971606
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.
Study: NCT00284869
Drug: LPS
Normalized name: ALPS LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02091739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT00405353
Drug: Androgel 10 grams of gel containing 100 mg of testosterone
Normalized name: testosterone Topical Gel [Androgel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: testosterone gel
Study: NCT03088358
Drug: TeaRx
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01357109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo bid
Study: NCT01566630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to RLX030 as intravenous infusion for 72 hours
Study: NCT01566630
Drug: RLX030
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLX030 1 mg/mL vials
Study: NCT03579914
Drug: intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive intravenous Placebo (saline) injection
Study: NCT05973318
Drug: Cosopt eye drops, 20 mg/mL + 5 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing schedule b.i.d.
Study: NCT00263484
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
Study: NCT01421498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
Study: NCT01077726
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg/m2 po bid on days 1-14 of each 3 week cycle
Study: NCT01016223
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo swallowed two puffs twice daily
Study: NCT01108510
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (RTV) 100 mg tablet administered orally once daily
Study: NCT01108510
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
Study: NCT01108510
Drug: COBI placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match COBI administered orally once daily
Study: NCT01108510
Drug: RTV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match RTV administered orally once daily